≥99% HPLCPre-filled pen

VIP + MOTS-c (Blend)

Name: VIP + MOTS-c (Blend)
Brand: Dripfy
Availability: InStock

What it is?

This is an investigational blend of two signalling peptides from different biology: VIP (Vasoactive Intestinal Peptide), an endogenous neuropeptide studied for immune and anti-inflammatory signalling, and MOTS-c, a mitochondrial-derived peptide investigated for metabolic and longevity-related pathways. The combination is research-grade and used only under physician direction.

Dripfy Advantage

Immune modulation: VIP is studied for anti-inflammatory effects via VPAC receptor signalling and regulation of T-cell and macrophage activity.
Metabolic signalling: MOTS-c is investigated for AMPK-associated pathways linked to insulin sensitivity and cellular energy balance.
Mitochondrial stress response: MOTS-c is examined in research for its role in cellular stress-adaptation signalling.
Combined framing: The blend overlays immune-regulatory and metabolic pathways, though the combination is not characterised in controlled human studies.

Research & Investigational Focus

Immune regulation: Investigated for anti-inflammatory and immune-balancing signalling (VIP component).
Metabolic pathways: Studied for insulin-sensitivity and mitochondrial-stress signalling (MOTS-c component).
Longevity research: Explored in preclinical exercise-mimetic and healthy-aging frameworks (MOTS-c).
Combined immune-metabolic frameworks: Positioned for physician-directed research combining both pathways.

Composition & Formulation

Format: Pre-filled pen
Purity: ≥99% by HPLC/MS
Supervision: Physician-directed use only

€624

Order by email

Submit an enquiry and we arrange the consultation, physician review and shipping. Physician recommendation required; not medical advice.

Purity: ≥99%
Form: Pre-filled pen
Download Certificate of Analysis: Certificate of Analysis available on request

Important medical notice

A physician recommendation is mandatory before use.
The information on this website is educational only and is not medical advice, diagnosis, or treatment.
Always consult a qualified physician before starting any peptide.
Dosing is individualised and determined by your treating physician.

Peptide Practice Guide

Each card summarises what the peptide is studied for and its evidence strength. It is not a recommendation. Dosing and suitability are decided by your physician.

VIP + MOTS-c (Blend)

Investigational immune/metabolic peptide blend (VIP + MOTS-c) · Pre-filled pen

D· Preliminary evidence

This blend combines two signalling peptides from different biology. VIP is an endogenous 28-amino-acid neuropeptide studied for immune-modulating and anti-inflammatory effects through VPAC receptor signalling and regulation of T-cell and macrophage activity. MOTS-c is a mitochondrial-derived peptide investigated for metabolic and longevity-related signalling, including AMPK activation and influence on insulin sensitivity and cellular stress responses. The blend is intended to overlay immune-regulatory and metabolic pathways, but the combination has not been characterised in controlled human studies.

Studied use areas

Investigated for immune regulation and anti-inflammatory signalling (VIP component)
Studied for insulin-sensitivity and mitochondrial-stress pathways (MOTS-c component)
Explored in preclinical longevity and exercise-mimetic research (MOTS-c)
Positioned for physician-directed research combining immune and metabolic pathways

Safety & status

Investigational blend; robust human trial data are lacking for both components, especially in combination
Combining compounds compounds the uncertainty — additive or interacting effects on immune and metabolic signalling are poorly characterised, so physician supervision is mandatory
Not for use in pregnancy or breastfeeding; VIP can cause vasodilation-related effects such as flushing or blood-pressure changes, so clinical oversight is required

⚕ Clinical note: This is educational information, not medical advice. This VIP + MOTS-c blend is investigational, and combining compounds increases the uncertainty; it is intended for physician-directed use only and is not a treatment for any immune, metabolic, or age-related condition.

Evidence: Grade D — investigational; limited human data, mainly preclinical · References: Lee C et al., Cell Metabolism, 2015; Delgado M, Ganea D, Amino Acids, 2013; Reynolds JC et al., Nature Communications, 2021